$4.96
Value $2.5B
CLOV and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$4.96
Value $2.5B
$285.75
Value $689B
Clover Health Investments (CLOV) has a market value of $2.5B and Johnson & Johnson (JNJ) $689B. Over the last year, with dividends, CLOV moved +97.6% and JNJ +50.3%. The P/E is 204.0 for CLOV and 42.8 for JNJ. Dividend yield: CLOV none, JNJ 1.85%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CLOV$2.5B
JNJ$689B
JNJ is 271 times CLOV
Revenue, 12 months
CLOV$2.7B
JNJ$99.3B
JNJ is 36 times CLOV
Net income, 12 months
CLOV$12M
JNJ$16.1B
JNJ is 1,293 times CLOV
Operating margin
CLOV0.4%
JNJ–
ROIC
CLOV2.8%
JNJ12.4%
9.6 points apart
P/E
CLOV204.0
JNJ42.8
CLOV is 4.8 times JNJ
Dividend yield
CLOV0.0%
JNJ1.8%
1.9 points apart
5-year return
CLOV-30.7%
JNJ+99.1%
129.8 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CLOV-30.7%
JNJ+99.1%
| Period | CLOVWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +97.6%Price +97.6% | +50.3%Price +47.0% |
| 3 years since November 13, 2023 | +451.7%+76.7% a yearPrice +451.7% | +110.8%+28.2% a yearPrice +93.6% |
| 5 years since November 12, 2021 | -30.7%-7.1% a yearPrice -30.7% | +99.1%+14.8% a yearPrice +73.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CLOVClover Health InvestmentsJNJJohnson & Johnson
| Price | $4.96 | $285.75 |
|---|---|---|
| Market value | $2.5B | $689B |
| Enterprise value (EV) | $2.2B | $716B |
| P/E | 204.0 | 42.8 |
| P/E, 5-year median | – | 21.9 |
| P/B | 6.5 | 8.5 |
| EV/EBIT | 177.7 | 40.4 |
| Free cash flow yield | 5.2% | 3.0% |
| Revenue, 12 months | $2.7B | $99.3B |
|---|---|---|
| Net income, 12 months | $12M | $16.1B |
| Free cash flow, 12 months | $132M | $20.6B |
| Earnings per share, 12 months | $0.02 | $6.59 |
| Revenue growth, year on year | 40.3% | 6.1% |
| Revenue growth a year, past | +23.4%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | – | 67.6% |
|---|---|---|
| Operating margin | 0.4% | – |
| Net margin | 0.4% | 16.2% |
| ROIC | 2.8% | 12.4% |
| ROE | 3.5% | 19.7% |
| Cash | $327M | $17.2B |
|---|---|---|
| Total debt | $3.3M | $44.7B |
| Net debt / EBITDA | -22.9 | 1.1 |
| Interest cover | – | 18.0× |
| Dividend yield | – | 1.8% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | 0.7% | 0.9% |
| Shareholder yield | 0.7% | 2.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($689B) is about 271.2 times Clover Health Investments ($2.5B), at today's prices.
Since November 12, 2021, CLOV's price moved -30.7% and JNJ's +73.2%. With dividends: CLOV -30.7% (-7.1% a year), JNJ +99.1% (+14.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Clover Health Investments and 1.85% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
At today's price, the P/E is 204.0 for CLOV and 42.8 for JNJ. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 0.4% for Clover Health Investments and 16.2% for Johnson & Johnson, and the operating margin 0.4% and –. Revenue was $2.7B and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.